It is noteworthy that patients with T2DM in the early stages of CKD had a significant decrease in FGF-23, contrary to what was previously reported, where 100% of patients with CKD in stage 5 had elevated levels of FGF-23 and PTH [30,31]. This evidence concerns the gene PTH and chronic kidney disease.